Ameriprise Financial Inc. lowered its holdings in Juno Therapeutics Inc (NASDAQ:JUNO) by 42.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 216,742 shares of the biopharmaceutical company’s stock after selling 157,868 shares during the period. Ameriprise Financial Inc. owned approximately 0.19% of Juno Therapeutics worth $9,723,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in JUNO. Advisor Group Inc. grew its holdings in Juno Therapeutics by 141.1% during the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,439 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 228 shares in the last quarter. Pacad Investment Ltd. acquired a new position in Juno Therapeutics during the 2nd quarter worth approximately $105,000. QS Investors LLC acquired a new position in Juno Therapeutics during the 2nd quarter worth approximately $135,000. Finally, Wellington Shields & Co. LLC acquired a new position in Juno Therapeutics during the 3rd quarter worth approximately $202,000. Hedge funds and other institutional investors own 69.94% of the company’s stock.
Juno Therapeutics Inc (JUNO) traded down $1.34 during mid-day trading on Friday, reaching $48.75. 1,510,000 shares of the company traded hands, compared to its average volume of 2,330,000. Juno Therapeutics Inc has a 1 year low of $18.90 and a 1 year high of $63.45. The stock has a market cap of $5,570.00, a P/E ratio of -14.38 and a beta of 2.32. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77.
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. Juno Therapeutics’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.57) EPS. research analysts anticipate that Juno Therapeutics Inc will post -4.02 EPS for the current year.
Several research analysts have commented on JUNO shares. SunTrust Banks upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 2nd. Morgan Stanley restated an “equal weight” rating and issued a $43.00 target price (up previously from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. Cowen restated a “buy” rating and issued a $49.00 target price on shares of Juno Therapeutics in a report on Friday, October 27th. Raymond James Financial upped their target price on shares of Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Finally, Wedbush restated an “outperform” rating and issued a $64.00 target price (up previously from $42.00) on shares of Juno Therapeutics in a report on Thursday, November 2nd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. Juno Therapeutics has a consensus rating of “Hold” and a consensus price target of $46.70.
In other Juno Therapeutics news, EVP Robert Azelby sold 6,666 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total transaction of $366,296.70. Following the completion of the transaction, the executive vice president now owns 79,998 shares in the company, valued at approximately $4,395,890.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Steve Harr sold 8,750 shares of the stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $44.76, for a total transaction of $391,650.00. Following the completion of the transaction, the chief financial officer now owns 772,082 shares of the company’s stock, valued at approximately $34,558,390.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,956 shares of company stock valued at $3,064,378. 15.08% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This news story was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/01/13/ameriprise-financial-inc-trims-stake-in-juno-therapeutics-inc-juno-updated-updated.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.